Clinical trials
Cell Therapy clinical trials
Below are recruiting cell therapy clinical trials, each written for real people, not researchers. We’re tracking 1,109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05336383RecruitingPhase 2
Radiation after prior CAR T for relapsed multiple myeloma
This trial tests giving “salvage” radiation (radiation meant to control remaining cancer) after you’ve already had BCMA CAR-T therapy for multiple myeloma. It’s for people whose PET or other scan still shows active myeloma at least 30 days after CAR-T, and who have a spot that radiation can target.
Houston, TexasAges 18 years+ - NCT07246304RecruitingEarly Phase 1
Cell therapy for DLL3-positive small cell lung cancer
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
Nanjing, JiangsuAges 18–75 - NCT05100095RecruitingPhase 2
Radiation schedule study for Merkel cell skin cancer
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Houston, TexasAges 18 years+ - NCT03882840RecruitingPhase 1/Phase 2
T-like NK cell therapy for cancers with low MHC-I
This early-stage trial tests a lab-made immune cell treatment (T-like NK cells) for advanced cancers that have low or missing MHC-I on their cells. Because the treatment aims to “re-activate” the immune system against these cancers, you may be eligible if your cancer matches this feature and you meet safety requirements.
Guangzhou, GuangdongAges 18 years+ - NCT06921980Recruiting
Cell therapy and brain function in AIHA
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07472023Enrolling by invitationEarly Phase 1
Stem cell therapy for hearing loss and tinnitus
This trial tests a regenerative stem cell treatment for people with hearing loss, tinnitus, or inner ear injury. It aims to see if the therapy can improve hearing or reduce symptoms.
New York, New YorkAges Any age - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06553898RecruitingPhase 1
CAR-T cell therapy for hard-to-treat kidney disease
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
Hangzhou, ZhejiangAges 2 years+ - NCT06044506RecruitingPhase 1
Natural killer cell therapy for liver cancer
This study tests an experimental therapy using your own natural killer cells to fight liver cancer. It may be an option if you have a specific stage of liver cancer and are generally in good health.
Jakarta Pusat, Jakarta Special Capital RegionAges 20–60 - NCT05472649Enrolling by invitation
Long-term follow-up after gene-modified cell therapy
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
Philadelphia, PennsylvaniaAges Any age - NCT06635330RecruitingPhase 1/Phase 2
CAR T cell therapy for children with relapsed B-cell leukemia
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
Tehran, Tehran ProvinceAges 2–18 - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT07748533RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune hemolytic anemia
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
TianjinAges 18–75 - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT02445534Recruiting
Registry for cell therapy in non-ischemic dilated heart muscle disease
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
LjubljanaAges 18–65 - NCT06790498Enrolling by invitation
Long-term follow-up after renal cell therapy for kidney disease
This study follows people who previously received an experimental treatment called REACT for chronic kidney disease in earlier clinical trials. Its goal is to monitor their health over time.
Meridian, IdahoAges 30–80 - NCT05043571RecruitingPhase 1
CAR T-cell therapy for relapsed T-cell leukemia
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
SingaporeAges 6 months–65 years - NCT04920474Recruiting
Share blood and transplant samples for future research
This study builds a library of transplant and related medical samples to help scientists learn how to improve cell therapies and care for marrow injury. You may be included because you are a donor, receive a transplant or cell therapy, or are treated for marrow toxic injury at participating centers.
New Brighton, MinnesotaAges Any age - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT03391778Enrolling by invitationPhase 1
Long-term follow-up for cell therapy participants
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Atlanta, GeorgiaAges Any age - NCT06431347Recruiting
Study on social factors in transplant care
This study looks at how social and financial challenges affect people getting a transplant or cell therapy at MD Anderson. Researchers want to talk to patients and their caregivers to better understand these challenges and improve care.
Houston, TexasAges 18 years+ - NCT05135091RecruitingPhase 3
Cell therapy trial for hard-to-control one-sided temporal lobe epilepsy
This Phase 3 study tests a neural cell therapy (NRTX-1001) for adults whose seizures come from one side of the hippocampus and have not improved with standard seizure medicines. The goal is to reduce seizure frequency and improve seizure control where other treatments have not worked.
Birmingham, AlabamaAges 18–75 - NCT06630611RecruitingPhase 2
A new immune cell therapy for melanoma, lung, and cervical cancer
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
BarcelonaAges 18 years+
Hear when a new Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cell therapy?
- Yes. Clin2 currently lists 1,109 recruiting cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.